S-nitroso Human Serum Albumin Attenuates Ischemia/Reperfusion Injury After Cardioplegic Arrest in Isolated Rabbit Hearts
By Semsroth, Severin; Fellner, Barbara; Trescher, Karola; Bernecker, Oliver Y.; Kalinowski, Leszek; Gasser, Harald; Hallström, Seth; Malinski, Tadeusz & Podesser, Bruno K.
Published in The Journal of Heart and Lung Transplantation
NULL
2005
Abstract
Background Depletion of nitric oxide (NO) is associated with ischemia/reperfusion injury. The novel NO donor, S-nitroso human serum albumin (S-NO-HSA), could bridge NO depletion during reperfusion in cardiac transplantation and minimize ischemia/reperfusion injury. Methods In an isolated erythrocyte-perfused working heart model, rabbit hearts were randomly assigned after assessment of hemodynamic baseline values to receive S-NO-HSA (0.2 μmol/100 ml, n = 8), L-arginine (10 mmol/100 ml, n = 8) or albumin (control) (0.2 μmol/100 ml, n = 8). After 20 minutes of infusion, the hearts were arrested and stored in Celsior (4°C) enriched with respective drugs for 6 hours, followed by 75 minutes of reperfusion. Hemodynamic values were assessed and biopsy specimens were taken to determine calcium-ionophore stimulated release of NO and superoxide. Results During early reperfusion, recovery of cardiac output (75% ± 6% vs 49% ± 5%, p < 0.05) and coronary flow (99% ± 8% vs 70% ± 5%, p < 0.05) were higher, and myocardial oxygen consumption was reduced in the S-NO-HSA Group compared with Control (4.08 ± 0.46 ml/min/0.1 kg vs 6.78 ± 0.38 ml/min/0.1 kg, p < 0.01). At the end of the experiment cardiac output (53% ± 5% vs 27% ± 5%, p < 0.01) was higher and left atrial pressure (115% ± 9% vs 150% ± 8%, p < 0.05) was lower in the S-NO-HSA Group compared with Control. NO release was increased (1,040 ± 50 nmol/liter and 1,070 ± 60 nmol/liter vs 860 ± 10 nmol/liter, p < 0.01) and superoxide release diminished (31 ± 5 nmol/liter and 38 ± 5 nmol/liter vs 64 ± 5 nmol/liter, p < .01) in the S-NO-HSA and L-arginine Groups compared with Control. Conclusion S-NO-HSA improved hemodynamic functions after prolonged hypothermic cardiac arrest by supplementing NO and thereby decreasing ischemia/reperfusion injury.
Microsoft is Ending Support for Windows 7
Microsoft will discontinue support for Windows 7 on January 14, 2020 which means Gamry will also be discontinuing support for Windows 7. If you are upgrading to Windows 10, like many companies and institutions, you need to be running Version 7 of our s oftware . Please note that only USB and Ethernet-based instruments can run in Version 7. Eligible users can download the latest version of our software through our online Client Portal .
If you haven't already registered your instrument, you can do so through the Client Portal .
Please email Technical Support if you have any questions regarding this transition. Please be sure to include your instrument model and serial number when contacting us.